Over the last decades, a greater understanding of the disease biology of non-small cell lung cancer (NSCLC) and the identification of recurrent oncogenic driver alterations has dramatically improved the therapeutic landscape. Indeed, we have moved away from a one-size-fits-all approach to a more personalized treatment strategy in which patients with a specific oncogenic driver mutations are treated with a suitable targeted therapy. However, to make this personalized treatment a reality, it needs to be accompanied by a fast and comprehensive molecular evaluation, allowing the accurate and timely detection of targetable oncogenic alterations. For this article, we asked Dr. Henry Paridaens, medical biologist at the Hôpital de la Citadelle in Liège to share how they currently approach the molecular testing of NSCLC patients.
In this interview Dr. Paridaens shares his insights on the following questions:
Read the complete interview here
This material is meant only for individuals allowed by law to prescribe or deliver medicines.
Copyright 2023 | PP-SE-BE-0149 NOV 2023
RP: Eli Lilly Benelux – Markiesstraat 1/4B Rue du Marquis, 1000 Brussel/Bruxelles
Top
